Program
zadavotide guraxetan
Also written as “FPI-2265” and “AZD2265 (FPI-2265)”.
Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Dec 20, 20214 company-led studies, 4 open or runningNext primary completion: Dec 23, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 44 open or running | phase 2since Dec 20, 2021 | Dec 20, 2021 | Dec 23, 2026phase 2 · NCT06402331 |
- Named in AstraZeneca’s own pipeline as
zadavotide guraxetan (AZD2265)
, phase 3, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2021First study: phase 2 study in Metastatic Castration Resistant Prostate CancerFirst studyNCT05219500 · 115 enrolled · United States
- Apr 26, 2024Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06402331 · 110 enrolled · United States
- Mar 21, 2025Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06909825 · 85 enrolled · Australia
- May 11, 2026Phase 2 study in Prostatic NeoplasmsNCT07590934 · 152 planned · United States, Australia, Germany and more
Ahead
- Dec 23, 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06402331
- May 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06909825
- Sep 25, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07590934
TargetBeta
“A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked to the bifunctional macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), and conjugated to the alpha-emitti…”NCIt, read by Claude
“A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07590934Prostatic Neoplasms · United States, Australia, Germany and more | 2 | Recruiting | Sep 25, 2029 | 152 |
| NCT06909825Metastatic Castration-resistant Prostate Cancer · Australia | 2 | Active, not recruiting | May 2027 | 85 |
| NCT06402331Metastatic Castration-resistant Prostate Cancer · United States | 2 | Active, not recruiting | Dec 23, 2026 | 110 |
| NCT05219500Metastatic Castration Resistant Prostate Cancer · United States | 2 | Active, not recruiting | May 30, 2025 | 115 |
How it is read
Names in the registry
- “FPI-2265”, 3 entries
- “AZD2265 (FPI-2265)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.